Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer
Laurus Labs has reported total income of Rs. 1,228.30 crores during the period ended September 30, 2024
Dr. Lal Path Labs has reported total income of Rs. 682.1 crores during the period ended September 30, 2024
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
The acquisition will strengthen the overall company’s position as leading global CRO services partner
he company will focus on production of any pharmaceutical and biotechnological products
He holds a Master’s in Management from the National University of Singapore
This office will be the central hub for all operations related to companies ethical pharmaceutical business
USFDA concludes inspection of Dr. Reddy's Laboratories R&D centre in Bachupally with zero observation
The primary objective was to evaluate safety and tolerability of Ropanicant in patients with MDD
Subscribe To Our Newsletter & Stay Updated
